| Document |
Document Title |
|
WO/2023/128597A1 |
The present invention relates to a physiological saline which includes N,N,N-trimethyl chitosan, thus having the advantages of an excellent anti-adhesion effect as well as an excellent antibacterial or hemostatic effect.
|
|
WO/2023/127824A1 |
The purpose of the present invention is to provide: a culturing method and a production method for a cell population containing neural crest cells, said methods being capable of stably mass producing neural crest cells from pluripotent s...
|
|
WO/2023/127853A1 |
Provided is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof (in formula (1), Ar is formula (Ar1) or (Ar2), and in these formulas, R1 and R2 each independently denote an alkyl, a haloalkyl, or a halogen...
|
|
WO/2023/125536A1 |
Provided in the present disclosure is a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound has a VEGF inhibitory effect, and can be used for preventing and treating diseases or conditions r...
|
|
WO/2023/124091A1 |
The present invention relates to a use of flunarizine and a method for controlling the number of intercellular mitochondria. The use comprises a use of the flunarizine in the removal of the intracellular mitochondria, and a use of the fl...
|
|
WO/2023/128121A1 |
The purpose of the present invention is to provide a composition for improving and treating obesity or liver-related diseases, comprising p-Coumaric acid as an active ingredient. In order to confirm that p-Coumaric acid (PCA) treats live...
|
|
WO/2023/123813A1 |
Drug-loaded microspheres as well as a preparation method therefor and the use thereof. The drug-loaded microspheres comprise a carrier loaded with a therapeutic agent, a coating layer covering the surface of the carrier and comprising an...
|
|
WO/2023/127883A1 |
The present invention provides a compound indicated by general formula (1) and having mPGES-1 inhibitory activity, a pharmaceutically acceptable salt thereof, or a solvate thereof (in the formula, R1 and R2 each independently indicate hy...
|
|
WO/2023/128680A1 |
The present invention discloses a composition employing guaiacol and 4',6,7-trimethoxyisoflavone for ameliorating pulmonary fibrosis, which inhibits the TGF-β1 signaling pathway in A549 cells, which are lung cancer-derived cells, to sup...
|
|
WO/2023/120552A1 |
The present specification discloses a reduced coenzyme Q10 product which does not require the formulation of reduced coenzyme Q10 and in which the oxidation of reduced coenzyme Q10 is suppressed. Also, the present specification discloses...
|
|
WO/2023/119301A1 |
Methods of treating fragile X syndrome by administering agents that reduce expression or function of various proteins are provided. Methods of determining suitability to be treated by the methods of the invention are also provided.
|
|
WO/2023/120516A1 |
[Problem] The purpose of the present invention is to provide a liquid composition for an oral cavity, said composition containing an alkali metal salt of a tricarboxylic acid, copper gluconate, and cetylpyridinium chloride, and suppressi...
|
|
WO/2023/121314A1 |
The present invention relates to a use of an Apios americana tuber extract for protection against alcoholic liver damage or alcoholic brain damage, and more particularly, provides a composition for protection against alcoholic liver dama...
|
|
WO/2023/121689A1 |
Various methods and compositions for treating single ventricle heart disease (SVHD) patients, including patients who have undergone Fontan surgery and who have Fontan circulation (Fontan patient), to improve exercise performance, especia...
|
|
WO/2023/120373A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and at least one docosahexaenoic acid and in which the bitterness derived from ergothioneine or the salt thereof and th...
|
|
WO/2023/120971A1 |
The present invention relates to a scaffold for preventing or treating liver fibrosis and, more specifically, to a scaffold, loaded with adipose-derived stem cells overexpressing PGC-1α, for preventing or treating liver fibrosis, the ad...
|
|
WO/2023/120696A1 |
The present invention provides a compound that exhibits an anticancer effect based on Checkpoint Kinase 1 (CHK1) inhibition. It is discovered that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof has a ...
|
|
WO/2023/120407A1 |
The purpose of the present invention is to provide a composition for suppressing production and/or accumulation of amyloid β. The present invention relates to the composition for suppressing production and/or accumulation of amyloid β,...
|
|
WO/2023/120558A1 |
The present specification discloses a method for storing reduced coenzyme Q10 (QH), the method being capable of suppressing oxidation. The first embodiment of the present invention relates to a method for storing QH, the method includi...
|
|
WO/2023/120517A1 |
[Problem] To provide a poultice in which the adhesive force of a paste layer to an adherend is strengthened. [Solution] A poultice comprising a support layer, a paste layer, and a release liner layer, wherein the paste layer comprises a ...
|
|
WO/2023/122040A1 |
The present invention relates to a polyelectrolyte complex, and compositions thereof, for use in the treatment or prevention of dental caries, early erosive damage, and enamel demineralization, and the promotion of enamel repair and remi...
|
|
WO/2023/121199A1 |
The present invention relates to: a biomarker composition for predicting susceptibility to a therapeutic agent for neurofibromatosis by using Ras activity; and a pharmaceutical composition for preventing or treating neurofibromatosis, co...
|
|
WO/2023/120704A1 |
The present disclosure provides a composition that is for improving a heart function and that contains a compound represented by formula (I), or an ester, oxide, prodrug, pharmaceutically acceptable salt or solvate thereof. Also provided...
|
|
WO/2023/120405A1 |
The purpose of the present invention is to provide a composition for minimizing the production and/or accumulation of amyloid β. The present invention relates to a composition for minimizing the production and/or accumulation of amyloid...
|
|
WO/2023/120376A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and a cereal oil or γ-oryzanol and in which the bitterness derived from ergothioneine or the salt thereof and the odor...
|
|
WO/2023/120557A1 |
The present description discloses a packaged body of reduced coenzyme Q10, which eliminates the need for formulating the reduced coenzyme Q10 into a preparation, does not undergo the oxidation of the reduced coenzyme Q10 and can be store...
|
|
WO/2023/121251A1 |
The present disclosure pertains to a compound useful for treating or palliating fibrosis, especially pulmonary fibrosis and a medical use thereof.
|
|
WO/2023/121519A1 |
The invention relates to the field of pharmaceuticals and medicine and concerns the use of 1-[2-(1-methylimidazole-4-yl)-ethyl]perhydroazine-2,6-dione or its pharmaceutically acceptable salts for the treatment and/or prophylaxis of COVID...
|
|
WO/2023/120555A1 |
The present description discloses a favorable means for suppressing oxidation of reduced coenzyme Q10 (QH) without requiring formulation of QH. At least one embodiment of the present invention relates to a method for storing reduced co...
|
|
WO/2023/120378A1 |
The purpose of the present invention is to provide an oral composition containing ergothioneine or a salt thereof and at least one arachidonic acid, the oral composition such that the bitterness derived from ergothioneine or salts thereo...
|
|
WO/2023/120367A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and in which the bitterness derived from ergothioneine or a salt thereof is reduced. The present invention pertains to ...
|
|
WO/2023/120331A1 |
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an ...
|
|
WO/2023/115149A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis, and/or inhibi...
|
|
WO/2023/120408A1 |
The purpose of the present invention is to provide a composition for suppressing or ameliorating cognitive function decline. The present invention pertains to a composition for suppressing or ameliorating cognitive function decline, the ...
|
|
WO/2023/115116A1 |
The present invention relates to polynucleotides for the generation of genetically modified plants, algae or plastids thereof that are capable of producing cannabinoids. In an aspect, the present invention also relates to methods of prod...
|
|
WO/2023/115150A1 |
This invention relates to compounds of formula (X) and salts, solvates, tautomers, N-oxides, stereoisomers, polymorphs and/or prodrugs thereof. Also disclosed is the use of the compounds of formula (X) to treat necroptosis and/or inhibit...
|
|
WO/2023/120368A1 |
The purpose of the present invention is to provide an oral composition which contains ergothioneine or a salt thereof and at least one eicosapentaenoic acid and in which the bitterness derived from ergothioneine or the salt thereof and t...
|
|
WO/2023/120370A1 |
The purpose of the present invention is to provide: an oral composition containing ergothioneine or a salt thereof and vitamin E and having minimized bitterness resulting from ergothioneine or a salt thereof and odor resulting from vitam...
|
|
WO/2023/117189A1 |
The invention relates to a composition for use in a method of treating a bacterial infection selected from a bacterial urinary tract infection, a bacterial respiratory tract infection, a bacterial soft tissue infection and a bacterial bo...
|
|
WO/2023/120553A1 |
The present description discloses a preferred means for preventing the oxidation of reduced coenzyme Q10 (QH) without requiring the formulation of QH into a preparation. One or more embodiments of the present invention relates to: a me...
|
|
WO/2023/120658A1 |
An enzyme according to the present invention has activity to convert uridine in RNA to cytidine. A complex according to the present invention comprises said enzyme and a sequence recognition module that causes uridine generated in mRNA b...
|
|
WO/2022/081795A9 |
A long-term delivery system for age-related macular degeneration (AMD) that can address the multifactorial nature of the disease. A polyurethane nanocapsule is disclosed that includes encapsulated molecules that treat AMD. The molecules ...
|
|
WO/2023/112657A1 |
The present invention provides a stabilizer that can suppress heat-induced hydrolysis of a nicotinamide mononucleotide. A stabilizer according to the present invention is for a nicotinamide mononucleotide and is characterized by compri...
|
|
WO/2023/112975A1 |
Provided is a lymphocyte function promoter. The lymphocyte function promoter contains at least one selected from the group consisting of a compound represented by general formula (1), a salt thereof, and a solvate of the same.
|
|
WO/2023/113540A1 |
The present invention provides novel monohydrochloride of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piper
idin-3-ol, oxalate of (2R, 3S)-2-(3-(4,5-dichloro-1H-benzo[d]imidazol-1-yl)propyl)piper
idin-3-ol, maleate of (2R...
|
|
WO/2023/113278A1 |
The present invention relates to: an anti-stress composition comprising at least one extract selected from the group consisting of peppermint extract and perilla frutescens extract as a natural extract mixture; and a use thereof. Using p...
|
|
WO/2023/113023A1 |
The present invention provides: a compound that has an inhibitory action against hematopoietic prostaglandin D synthase (H-PGDS), and thus is useful for the prevention and treatment of diseases in which the enzyme is involved; and a phar...
|
|
WO/2023/112912A1 |
The purpose of the present invention is to provide a conjugate compound capable of inhibiting complement activation. The conjugate compound contains: a polymer (A) which has a constitutional unit derived from a monomer (a) having two or ...
|
|
WO/2023/115060A1 |
Provided herein are psychoplastogens which can be useful for treating hearing loss.
|
|
WO/2023/112454A1 |
Provided are: an intestinal tumor suppressor which comprises a dectin-1inhibitor or β-glucan having a dectin-1 inhibition activity and can suppress intestinal tumor through the inhibition of dectin-1; a PGE2 production inhibitor which c...
|
